Tirzepatide FDA Approval Timeline: From Development to Market

Tirzepatide's journey from laboratory to pharmacy shelves is a story of scientific innovation and clinical success. Here's the complete timeline.

Development Timeline

2016

• Eli Lilly initiates Phase 1 clinical trials for LY3298176 (tirzepatide)
• First-in-class dual GIP/GLP-1 receptor agonist concept validated

2018

• Phase 2 trial results published showing promising efficacy
• SURPASS clinical trial program initiated for type 2 diabetes

2020

• SURPASS-1 and SURPASS-2 trials completed
• SURMOUNT clinical trial program initiated for obesity

2021

• Full SURPASS trial results published in major medical journals
• FDA Breakthrough Therapy designation for type 2 diabetes
• New Drug Application (NDA) submitted to FDA for T2D

May 2022

• FDA approves Mounjaro for type 2 diabetes
• First dual GIP/GLP-1 agonist to reach the market
• Launched at a list price of ~$974/month

July 2022

• SURMOUNT-1 results published in New England Journal of Medicine
• Results described as "game-changing" for obesity medicine

October 2023

• FDA accepts supplemental NDA for chronic weight management
• Priority review granted

November 2023

• FDA approves Zepbound for chronic weight management
• Approved for adults with BMI ≥30 or BMI ≥27 with comorbidities

2024

• Supply constraints begin to ease
• SURMOUNT-3 and SURMOUNT-4 results published
• SURMOUNT-OSA results show sleep apnea improvements
• LillyDirect platform launched for direct-to-patient access
• Breakthrough Therapy designation for obstructive sleep apnea

2025 (Expected)

• SURPASS-CVOT cardiovascular outcomes data expected
• Potential additional indications (MASH/NAFLD, sleep apnea)
• Continued expansion of manufacturing capacity